CorMedix (CRMD) news
Recent news
CorMedix shares jump 21.5% after Q2 revenue beat
AInvest Wire · Aug 13, 2026Cormedix raises FY adjusted EBITDA guidance to $125M to $140M
CorMedix Inc. (NASDAQ:CRMD) has raised its full-year 2026 adjusted EBITDA guidance to a range of $115 million to $135 million, reflecting stronger-than-expected performance in the first quarter. This update comes despite the company missing first-quarter earnings estimates, as revenue surged 226%…
AInvest Wire · Aug 13, 2026Cormedix 2Q EPS 29c, est. 24c
CorMedix Inc. (Nasdaq: CRMD) reported second-quarter earnings per share (EPS) of $0.29, exceeding the estimated $0.24 . The company’s financial performance reflects continued progress in its commercialization efforts and operational execution. For the second quarter of 2025, CorMedix recorded $39.7…
AInvest Wire · Aug 13, 2026Cormedix: Michael Seckler has left company
CorMedix Therapeutics (Nasdaq: CRMD) has announced that Michael Seckler, who joined the company in January 2026 as Executive Vice President and Chief Commercial Officer, has left the organization. Mr. Seckler’s departure marks a transition in the company’s leadership structure, though no further…
AInvest Wire · Jul 2, 2026Cormedix names Hurlburt as chief operating & commercial officer
AInvest Wire · Jul 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.